Richiedi una copia del documento: Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseases: Response to: Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15:1677–1683

L’utente di Usiena air si impegna ad utilizzare i documenti ricevuti in full-text esclusivamente per scopi di ricerca e/o studio. E’ comunque escluso qualsiasi uso commerciale.

Captcha code
Annulla